|
Announcements
NOVARTIS DIAGNOSTICS SELECTS CLINIVATION WORLDVIEW®.
Innovative leader in making
ground-breaking discoveries and developing innovative solutions
for the screening and prevention of infectious diseases selects
clinivation WorldView as its most comprehensive, authoritative,
and up-to-date resource for building its medical product submissions
and registrations worldwide.
Natick, MA, January 6, 2010
- clinivation, Inc. announced today Novartis Diagnostics
a subsidiary of Novartis AG has selected the clinivation WorldView
enterprise solution for On-Demand Global Regulatory Intelligence.
“Novartis Diagnostics is an innovative leader in making ground-breaking
discoveries and developing innovative solutions for the screening
and prevention of infectious diseases. We are pleased that they
have chosen clinivation WorldView for comprehensive, authoritative,
and up-to-date global regulatory intelligence,” said Richard Morroney,
R.A.C., C.Q.A., clinivation's Vice President, Global Market Clearance
Solutions.
About clinivation WorldView On-Demand Global Regulatory Intelligence
Clinivation WorldView is the medical device and diagnostic industry's most comprehensive,
authoritative, and up-to-date enterprise solution for On-Demand Global Regulatory
Intelligence. Providing clear, step-by-step market clearance regulations, processes,
and guidance for >99% of the world markets, only clinivation WorldView delivers
tried-and-true intelligence from certified, practicing professionals with real-world
experience.
About Novartis Diagnostics
Novartis Diagnostics is a leader in making ground-breaking discoveries
and developing innovative solutions for the screening and prevention
of infectious diseases. Novartis Diagnostics creates innovative
diagnostics to detect, prevent and predict disease and to improve
medical outcomes. The company's products are used to test more
than 25 million blood donations a year, preventing HIV-1, hepatitis
and West Nile Virus transmission through transfusions. Novartis
Diagnostics is a subsidiary of Novartis AG.
For more information about Novartis Diagnostics, please visit
www.novartisdiagnostics.com.
About clinivation, Inc. Clinivation
is the leading provider of integrated solutions that enable global market clearance.
Guided by our singular vision - "Excellence in Market Clearance" - clinivation
accelerates the entire market clearance cycle to advance new worldwide revenue
and achieve new milestones of enterprise value. Used in over 1,000,000 product
registrations by more than 100 companies worldwide, clinivation's end-to-end technology
and services deliver on our vision by eliminating revenue traps from global market
clearance operations, increasing process velocity with on-demand regulatory intelligence,
automating clearance-driven business controls, simplifying content unification
into market clearance applications, aligning quality systems with global market
clearance priorities, streamlining clinical development with clearance-focused
trials, and enabling management with key performance indicators for continuous
improvement and effective governance. The world's leading medical device,
diagnostics, hospital supply, and dental supply companies select clinivation because
of our medtech industry focus and our unique, integrated solutions that seamlessly
adapt to existing business processes and enterprise infrastructure- without the
need to write custom code. Our core brands include the clinivation Global xi
market clearance platform, clinivation WorldView on-demand regulatory intelligence,
and clinivation Clinical Suite and clinivation Registry Suite electronic data
capture and clinical data management software. Founded in 1999, the company
is headquartered in Natick, Massachusetts, with regional offices in North America
and Asia. Visit clinivation online at www.clinivation.com For
further information: For more information on clinivation's
integrated solutions that enable global market clearance, please click
here or call us at 508.655.6560. |